Health
GSK Lifts Long-Term Outlook on Drug Pipeline, Buys Back Shares
- British drugmaker expects over £40 billion in sales by 2031
- Cites progress on late stage pipeline including oncology drugs
This article is for subscribers only.
GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around the drug pipeline.
The British drugmaker boosted its 2031 sales forecast to over £40 billion, up from the more than £38 billion it previously expected. GSK said this reflected progress in late stage drug development, including several oncology medicines.